In the present study, we explored the vulnerability and adaptive responses of EML4-ALK-harbouring NSCLC cell lines upon acute ALK inhibition with LOR, the latest clinically approved ALK-TKI inhibitor. Here, EML4 is linked to non-small cell lung carcinoma.